ARROWHEAD PHARMACEUTICALS, INC.
About ARROWHEAD PHARMACEUTICALS, INC.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $829.4M
- Net income
- -$1.6M
- Total assets
- $1.4B
- Market cap
- $10.3B
- Operating margin
- 11.9%
- Net margin
- 3.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $829.4M
- Operating expenses
- $731.1M
- Operating income
- $98.3M
- Income tax
- $21.4M
- Net income
- $30.1M
- EPS (basic)
- $-0.01
- EPS (diluted)
- $-0.01
Balance sheet
- Total assets
- $1.4B
- Current assets
- $950.6M
- Total liabilities
- $881.9M
- Current liabilities
- $195.5M
- Shareholders’ equity
- $503.4M
Cash flow
- Operating cash flow
- $179.6M
- Investing cash flow
- -$129.3M
- Financing cash flow
- $74.0M
- Net cash flow
- $123.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $10.3B
- EPS (diluted)
- $-0.01
- Shares outstanding
- 139.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 1, 1995
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $1.6M in FY2025.
- Revenue grew 500% from FY2021 to FY2025.
- Trading 7% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ARROWHEAD PHARMACEUTICALS, INC..
Write a review
News about ARROWHEAD PHARMACEUTICALS, INC.
News & sentiment via Polygon.io
